Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25968444 | 0.86 | KDM4E (0.74) | KDM4EALDH1A1KMT2ALMNAHTT | |
| SCHEMBL3599380 | 0.82 | ACHE (0.69) | KDM4EALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL3959065 | 0.80 | ACHE (0.66) | KDM4EALDH1A1KMT2ASMN1; SMN2ACHE | |
| SCHEMBL21084415 | 0.79 | KDM4E (0.95) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3307108 | 0.79 | ACHE (0.62) | KDM4EALDH1A1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL24163287 | 0.78 | KDM4E (0.64) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3773954 | 0.78 | MEN1 (0.62) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL7130439 | 0.77 | LMNA (0.72) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3709310 | 0.77 | RECQL (0.70) | KDM4EALDH1A1TSHRSMN1; SMN2ACHE | |
| SCHEMBL10164227 | 0.77 | KMT2A (0.59) | KDM4EMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | THE CLEVELAND CLINIC FOUNDATION | 2023-08-17 | — | — | US | disclosed |
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | THE CLEVELAND CLINIC FOUNDATION | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | CHAT, DCX, GAP43 | KDM4E 3073/4885ALDH1A1 611/4885MEN1 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.